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Abstract.  A small library of ferrocene containing amides have been synthesized using 
standard amide coupling chemistry with ferrocenylamine. Ferrocene analogues of known 
bioactive adamantylamides were shown to be effective cannabinoid receptor (CB1 and CB2) 
agonists, displaying, in many cases, single digit nM potency. Three final ferrocene-containing 
derivatives have been characterized in the solid state by X-ray crystallography and display 
intramolecular hydrogen bonding of the type NH---C=O. N-Methylation of the amide,  
confirmed by X-ray crystallography, leads to loss of hydrogen bonding and biological 
activity. 
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Introduction. Cannabinoid receptors, belonging to the G-protein-coupled receptors (GPCR) 
superfamily, consist of two subtypes CB1 and CB2. The latter are widely distributed in the 
immune system, whereas CB1 receptors are predominately located in the central nervous 
system.1-3 According to their high distribution in the immune system, CB2 receptors have 
been suggested to play a crucial role in the modulation of inflammation.4 Overexpression of 
CB2 receptors is observed after an inflammation stimuli.
5 Activation of CB2 receptors is 
accompanied by the suppression of macrophages activation, the blockage of calcium signals 
in nociceptors and the modulation of nociceptor excitability, associated with anti-
inflammation, anti-nociception, neuroprotection, gastroprotection or other protective effects.6, 
7 Moreover, activation of CB2 receptors rather than CB1 receptors has been identified to be 
devoid of cannabimimetic side effects (such as hypomotility, hypothermia and catalepsy).8 
At the molecular level, the CB2 receptor is coupled to a Gi/0 subunit that inhibits adenylyl 
cyclase and cyclic adenosine monophosphate (cAMP) production. According to their 
functionality, ligands for CB2 receptors can be classified as : (1) agonists, which activate CB2 
receptors and then repress adenylyl cyclase, thereby resulting in a decrease in cAMP 
concentration, (2) antagonists, which prevent the activation of receptors by 
endocannabinoids, and (3) inverse agonists, which reduce CB2 receptor activity and induce an 
accumulation of cAMP through upregulation of adenylyl cyclase activity.9, 10 CB2 agonists 
have been demonstrated to produce anti-inflammatory, analgesic, and other protective 
efficacies by the modulation of calcium signal and nociceptor excitability.6, 11 CB2 
antagonists/inverse agonists have been argued to show potential in the treatment of bone-
dependent disorders (such as osteoporosis) through regulation of bone proliferation.12-15 In 
addition, inverse agonists have been identified to exert immunomodulatory ability and 
therapeutic potential for inflammation (such as carrageenan-induced paw swelling) through 
regulating the migration of inflammatory cells and immune cells, including leukocytes.12, 13, 16 
Accordingly, the development of CB2 ligands has been viewed as an interesting approach for 
the treatment of a wide range of nervous or immune system disorders. Over the last decades, 
research on CB2 ligands has significantly progressed. Several CB2 agonists, antagonists, and 
inverse agonists have been disclosed. (R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone 1 (WIN 
55,212-2, Figure 1), one of the most potent dual CB1/CB2 agonists to date, has been widely 
used for the investigation of cannabinoid receptor-dependent biological responses.17 It exerts 
antinociceptive efficacy in a model of neuropathic spinal cord injury and inhibits the 
proliferation of cancer cells.18, 19 (2-Iodo-5-nitrophenyl)-[1-[(1-methylpiperidin-2-
yl)methyl]indol-3-yl]methanone 2 (AM-1241, Figure 1), an aminoalkylindole derivative, has 
been demonstrated to be a potent selective CB2 agonist and shows efficacy in a variety of in 
vivo pain and inflammation models, including spinal nerve ligation (SNL)-induced 
nociception and 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis.20, 21 Compound 3 
(SR144528, Figure 1) was the first selective CB2 antagonist, discovered by Sanofi Research, 
and was later identified to possess temperature-dependent inverse agonist properties.22-24 It 
was further identified to up-regulate the expression of CB2 receptors.
23, 25 6-Iodopravadoline 
4 (AM630, Figure 1), a potent selective CB2 inverse agonist, showed potential to attenuate 
titanium particle-induced osteoporosis.26, 27 Two other well-known CB2 inverse agonists 5 
(Sch225336, Figure 1) and 6 (Sch414319, Figure 1) manifest the ability to relieve 
inflammation by modulating the migration of immune cells.12, 16 
 
Figure 1. Structures of representative CB2 ligands. 
 
 
Previously, 4-oxo-1,4-dihydropyridine and 4-oxo-1,4-dihydroquinoline have been 
demonstrated to be favorable scaffolds for the design of potent CB2 agonists or inverse 
agonists.28-31 Specifically, derivatives bearing a 1-adamantylamine group were determined to 
be potent and functionally-selective CB2 ligands. For instance, the 4-oxo-1,4-
dihydroquinoline derivative 7 (Figure 2) was identified as a CB2 agonist (Ki = 16.4 nM, Emax 
(GTPγS) = 125.6%). In the 4-oxo-1,4-dihydropyridines series, derivative 8 (Figure 2) showed 
partial agonist properties, while compound 9 (Figure 2) was identified as a full agonist for 
CB2 receptors (Ki = 20 and 29 nM, Emax (GTPγS) = 148% and 212%, EC50 (GTPγS) = 5.5 nM 
and 12.2 nM, respectively).32 These compounds showed good selectivity over CB1 receptors 
(Selectivity index (SI) > 100).30 Conversely, another 4-oxo-1,4-dihydropyridine derivative 10 
(Ki = 4 nM, Emax (GTPγS) = 39%, EC50 (GTPγS) = 3.2 nM,  SI = 148, Figure 2) bearing a 
phenyl ring instead of an alkyl group at C6 position behaves as a CB2 inverse agonist.
30 
Depending on the substituent at position-6 (methyl, tert-butyl or phenyl group), the biological 
response changes from CB2 agonist to CB2 inverse agonist.  This switch is supposedly due to 
interactions between the 6-substituted phenyl ring and Trp258 of the receptor. It has been 
demonstrated that the phenyl ring at the C6 position of 4-oxo-1,4-dihydropyridines confers 
inverse agonist properties through the stabilization of χ1 torsion of the Trp258 side chain in 
its inactive conformation,30 thereby inducing a CB2-mediated inverse biological response 
associated with the upregulated production of cAMP. 
 
Figure 2. Structures of previously developed 4-oxo-1,4-dihydropyridine/4-oxo-1,4-
dihydroquinoline-derived CB2 ligands containing an adamantylamine group. 
 
Ferrocene, an organometallic complex, shows advantageous properties for the design of 
potential pharmaceutical agents. For instance, its lipophilicity (logP = 2.66 (ferrocene) vs. 
2.69 for adamantane) endows its derivatives with suitable bioavailability and membrane 
penetration.33-35 The rotation of the aromatic cyclopentadienyl ring confers conformation 
diversity on ferrocene (staggered or overlapped conformation), which is favorable for 
orientating ferrocene-derived ligands into their receptor pockets.36 Additionally, ferrocene 
derivatives have been identified to produce a variety of biological responses, including 
anticancer,36-47 antimalarial,36, 48 antioxidant,49 antibacterial50 and glucose sensing 
properties.51 Thus, development of ferrocene derivatives could be regarded as an interesting 
approach to discover potential novel pharmaceutical agents and tool compounds. 
Based on these interesting results, we decided to observe the influence of the replacement of 
the 1-adamantyl group by a ferrocene unit. Herein, we report the synthesis and biological 
evaluation of a novel series of ferrocenyl 4-oxo-1,4-dihydropyridine and dihydroquinoline 
derivatives. Both series of compounds were easily synthesized by standard amide coupling 
protocols and were characterized by 1H and 13C NMR spectroscopy, mass spectrometry and 
combustion analysis, for solids, or by percentage purity by LCMS for oils (Scheme 1). In the 
case of solids, four of these air-stable derivatives were further characterized in the solid state 
by X-ray crystallography, confirming the presence of intramolecular hydrogen bond between 
the ketone and amide functionalities, which is also observed in solution-based studies (=ca. 
11.5 ppm in their 1H NMR spectra). Compound 11b exhibits some minor disorder in the solid 
state with the substituent pentyl chain adopting two slightly different conformations in the 
approximate ratio 57:43. 
 
Scheme 1. Synthesis of ferrocenylamides. 
      
       
Figure 3. Solid state structures of ferrocene products: 11a (top), 11b (bottom left), and 11c 
(bottom right). 
 
Often, an intramolecular hydrogen bond acts as a conformational lock, stabilizing an active 
conformation of a molecule and improving its binding to a receptor or enzyme.52 Given that 
all the ferrocenes synthesized herein display such hydrogen bonding (Figure 3) we decided to 
synthesize a N-Me amide derivative 13a to compare its receptor binding to its NH-amide 
precursor 11a (Scheme 2). The 1H NMR spectrum of 13a, even at variable temperature (VT), 
showed a broad signal and was indicative of a fluxional molecule. Nevertheless, we 
confirmed its structure by X-ray crystallography (Scheme 2), which clearly shows a change 
in conformation brought about by the loss of the intramolecular H-bond. 
 
 Scheme 2. N-Methylation reaction of a ferrocenyl amide.  
 
The affinities of each synthesized compound for both CB1 and CB2 receptors were 
determined by a competitive radioligand displacement assay using the dual CB1/CB2 ligand 
[3H]-CP55,940.53, 54  
Compounds 11a, 11b, 11c, 12a, 12b, and 12c manifest good CB2 affinity (5 nM < Ki < 220 
nM). Specifically, for the 4-oxo-1,4-dihydroquinoline derivatives, a lipophilic alkyl chain on 
the endocyclic nitrogen (11a, Ki = 36.7 nM; 11b, Ki = 10.9 nM) gives a superior affinity to 
the compound than a hydrophilic morpholinoethyl group (11c, Ki = 133.6 nM). As expected, 
the methylation of the amide group of compound 11a brought about a sharp decrease in 
affinity for CB2 (13a, Ki > 1 μM). In the 4-oxo-1,4-dihydropyridine series , a bulky group 
(such as a tert-butyl or a phenyl group, 12b, Ki = 59.5 nM and 12c, Ki = 5.2 nM, respectively) 
is preferred for CB2 affinity rather than a small alkyl group (such as a methyl, 12a, Ki = 218.8 
nM) at the C6 position. Compared to previously developed CB2 ligands (such as 7, 8, 9 and 
10, SI > 100), the replacement of the 1-adamantyl group by a ferrocene seems to maintain the 
CB2 affinity of the molecules, with only a weak decrease in affinity for 12a compared to 8. 
However, it brings about an obvious increase in affinity for CB1 receptors (12a, 12b, and 12c, 
SI < 15). 
Compounds displaying potent CB2 affinity were further studied for their functionality by 
cAMP assays in Chinese hamster ovary cells expressing CB2 receptors (CHO-CB2).
55-57 Cells 
were treated with forskolin in order to activate adenylyl cyclase and cAMP production. In 
Table 1, the maximum efficacy (Emax) of a compound represents the maximum response at 
10-6 M and is expressed as the percentage of forskolin-induced cAMP production. Compound 
potency was also evaluated in the presence of increasing concentrations of each compound 
and was expressed as the concentration that exhibits the half-maximal response (EC50). 
Although 4-oxo-1,4-dihydroquinolines 11a and 11b were determined to show potent affinity 
for CB2 receptors, their binding to the receptors did not significantly affect CB2-mediated 
regulation of cAMP production (Emax cAMP = 74% and 78%, respectively). The replacement 
of the N-substituted alkyl group of 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives by 
an N-ethyl morpholine gave rise to an obvious increase in CB2 agonist functionality of the 
molecule (11c, Emax cAMP = 52%), which might be attributed to probable hydrogen binding 
interactions between morpholine and CB2 receptors. The 4-oxo-1,4-dihydropyridine-3-
carboxamide derivatives bearing an alkyl substituent at C6 position (12a and 12b) show CB2 
agonist properties (Emax cAMP = 50% and 55%, respectively). In the 4-oxo-1,4-
dihydropyridine-3-carboxamide series, compound 12c (Emax cAMP = 500%), bearing a 6-
substituted phenyl group instead of an alkyl substituent, appears to behave as a CB2 inverse 
agonist. These observations are consistent with our previous results.4 It is noteworthy that 
12c-induced accumulation of cAMP (EC50 cAMP = 12 nM) is approximately 65-fold more 
greater than for compound 4 (EC50 cAMP = 785 nM), one of the most potent CB2 inverse 
agonists reported to date. Interestingly, as illustrated in Table 1, replacement of the 1-
adamantyl group (8, 9, and 10) by a ferrocene (12a, 12b, and 12c) does not alter the 
functionality of these compounds and their ability to regulate cAMP formation. 
The cytotoxicity of these compounds was determined at 10 μM using a cell proliferation 
assay on Chinese hamster ovary cells wild type (CHO-WT), CHO-CB2 and human colorectal 
adenocarcinoma cells HT29. This test is based on a colorimetric method, which measures the 
activity of cellular enzymes that reduce the tetrazolium dye (MTS, yellow) to its insoluble 
formazan giving a purple color. This assay measures cellular metabolic activity via NADPH-
dependent cellular oxidoreductase enzymes and reflects, under defined conditions, the 
number of viable cells. No significant cytotoxicity was observed for these new compounds 
except for derivative 11c, which slightly inhibited the proliferation of HT29 cells (48% at 10 
µM).58 
 
Table 1. Affinities (Ki values), maximum efficacy (Emax), and/or half-maximal response 
(EC50) of compounds 8-10, 11a-c, 12a-c, 13a and reference compounds (WIN-55,212-2, 
AM630) towards hCB2 and hCB1 cannabinoid receptors, selectivity ratios hCB2 versus hCB1, 
and cytotoxicity on CHO-WT, CHO-CB2, and HT29 cells 
 
 
Compounds 
Substituents hCB2 and hCB1 binding assays
a CB2 cAMP assay
a Cytotoxicity assays 
% inhibition at 10 μM 
R1 R2 CB2 Ki (nM) CB1 Ki (nM) 
Ratio 
CB1/CB2 
Emax (%)
b EC50 (nM) CHO-WT CHO-CB2 HT29 
8   20 ± 3c > 3000c > 150c 63 ± 8 8.0 ± 3.3 N. D.d N. D.d N. D.d 
9   29 ± 3c > 3000c > 103c 51 ± 14 21 ± 10 N. D.d N. D.d N. D.d 
10   4.0 ± 0.4c 592 ± 97c 148c 458 ± 106 36 ± 6 N. D.d N. D.d N. D.d 
11a Cyclohexyl H 36.7 ± 20.4 372.2 ± 27.6 10.1 74 ± 13 N. D.d 0 0 0 
11b n-Pentyl H 10.9 ± 2.2 5.5 ± 2.0 0.5 78 ± 14 N. D.d 0 0 0 
11c Morpholinoethyl H 133.6 ± 25.6 475.4 ± 51.7 3.6 52 ± 9 9.9 ± 1.5 0 5 48 
13a Cyclohexyl Methyl > 1000 N. D.d N. D.d N. D.d N. D.d 0 0 0 
 R3 R4         
12a n-Pentyl Methyl 218.8 ± 15.8 204.9 ± 33.7 0.9 50 ± 14 11.0 ± 4.9 0 0 1 
12b n-Pentyl t-Butyl 59.5 ± 13.8 747.2 ± 106.1 12.6 55 ± 13 21 ± 14 0 0 0 
12c n-Pentyl Phenyl 5.2 ± 0.4 23.4 ± 1.9 4.5 500 ± 32 12.0 ± 1.5 0 0 0 
Forskolin      100     
WIN55,212-2   6.9 ± 2.0 13.9 ± 4.0 2.0 45 ± 7 4.3 ± 1.1    
AM630   31.2 ± 12.4e 5152 ± 567e 165e 232 ± 79 785 ± 7    
a Data represent the mean ± SEM of three or four experiments performed in duplicate or triplicate. 
b Emax values are expressed as a percentage of forskolin-induced cAMP production. 
c Data from Ref 30.  
d N. D. means not determined. 
e Data from Ref 26. 
 Conclusions. A small library of ferrocenylamine-based 4-oxo-1,4-dihydropyridine and 
dihydroquinoline derivatives has been synthesized. Many display potency even at low (nM) 
concentrations vs. CB1 and CB2 receptors. A crucial intramolecular (NH---O=C) hydrogen 
bond, evidenced in both solution and the solid state, appears to be important for receptor 
binding since N-methylation, and subsequent loss of this hydrogen bond, leads to a loss of 
affinity. This study demonstrates that aminoferrocene-based compounds can replace 
adamantanyl amines in GPCR-targeting bioorganometallic agents. Whether or not this effect 
is simply a size/shape similarity of a ferrocene moiety compared to an adamantly group or if 
there is the induction of reactive oxygen species (ROS) as is often the case with ferrocenyl 
groups in bioorganometallic chemistry is beyond the scope of this study but the latter cannot 
be ruled out.41, 44, 59-61 
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Experimental 
Solvents and reagents were purchased from commercial suppliers and were used without 
purification. Ferrrocenylamine was purchased from TCI, UK and used as such. All reactions 
were performed in a fume hood. NMR spectra were recorded on Varian 500 MHz or 400 
MHz spectrometers and chemical shifts are reported in ppm, usually referenced to TMS as an 
internal standard. LCMS were performed on a 5 µm C18 110 Å column and percentage 
purities were ran over 30 minutes in water/acetonitrile with 0.1% formic acid (5 min at 5%, 
5%-95% over 20 min, 5 min at 95%) with the UV detector at 254 nm. High resolution mass 
spectrometry (HRMS) were performed by the EPSRC National Mass Spectrometry Facility, 
University of Swansea. Elemental Analyses were conducted by Stephen Boyer (London 
Metropolitan University). 
1-Cyclohexyl-N-ferrocenyl-4-oxo-N-ferrocenyl-1,4-dihydroquinoline-3-carboxamide 
(11a). The title compound was prepared by a coupling reaction; 1-cyclohexyl-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (271 mg, 1 mmol) was reacted with HOBt (68 mg, 0.5 
mmol) , HBTU (570 mg, 1.5 mmol) and DIPEA (0.35 mL) in CHCl3 solution (20 mL). The 
reaction mixture was stirred at RT for 45 min. and then aminoferrocene (241 mg, 1.2 mmol) 
was added and the mixture was stirred for 24 h. Afterwards, the reaction mixture was washed 
with NaOH (0.5N, 20 mL), HCl (1N, 20 mL) and H2O (20 mL). The organic layer was dried 
with MgSO4 and evaporated to 3 mL volume and purified by column chromatography. The 
orange band was eluted with a hexane: ethyl acetate (7:3) mixture, and was collected and 
evaporated to dryness. The yield was 340 mg, 75% (orange solid). Crystallization by 
diffusion between CH2Cl2 and hexane provided orange crystals.  
1H NMR (CDCl3) 500 MHz. 
 = 11.56 (1H, s, NH), 9.04 (1H, s, CH), 8.62 (1H, dd, 3JHH = 8.1, 4JHH = 1.6, CH), 7.78 – 
7.76 (1H, m, CH), 7.68 (1H, d, 3JHH = 8.7, CH), 7.55 - 7.53(1H, m, CH), 4.82 (2H, d, 
3JHH = 
1.8 , CH2), 4.53- 4.51 (1H, m, CH), 4.19 (5H, s, Cp), 4.05 (2H, d, 
3JHH = 1.8, CH2), 2.22- 2.19 
(2H, m, CH2), 2.08 – 2.05 (2H, m, CH2), 1.89 – 1.86 (3H, m, CH2+CH), 1.60-1.57 (2H, m, 
CH2), 1.36 - 1.34 (1H, m, CH). 
13C NMR (CDCl3) 126 MHz.  = 176.2, 163.2, 143.1, 139.4, 
132.8, 128.1, 127.6, 125.0, 115.2, 111.8, 94.5, 69.2, 64.5, 61.8, 59.8, 32.8, 25.9, 25.2. 
HRMS-ESI (m/z) found 455.1396, calcd for [C26H26FeN2O2 + H]
+  455.1416. Elemental 
Analysis: calcd (%)  C, 68.73; H, 5.77; N, 6.17 for C26H26FeN2O2; fnd (%) C, 68.50; H, 
5.89; N, 6.06. 
N-Ferrocenyl-4-oxo-1-pentyl-1,4-dihydroquinoline-3-carboxamide (11b). 4-Oxo-1-
pentyl-1,4-dihydroquinoline-3-carboxylic acid (25.9 mg, 0.1 mmol) was reacted with HOBt 
(6.8 mg, 0.05 mmol), HBTU (57 mg, 0.15 mmol) and DIPEA (0.035 mL)  in CHCl3 solution 
(2 mL). The reaction mixture was stirred at RT for 45 min. and then aminoferrocene (24.1 
mg, 0.12 mmol) was added and the mixture was stirred for 24 h. Work-up was as above. The 
orange band was eluted with a hexane: ethyl acetate (1:1) mixture, and was collected and 
evaporated to dryness. The yield was 19 mg, 43% (orange solid). Crystallization by diffusion 
between CH2Cl2 and hexane provided yellow crystals. 
1H NMR (CDCl3) 500MHz.  = 11.51 
(1H, s, NH), 8.84 (1H, s, CH), 8.61 - 8.58 (1H, m, CH), 7.79 – 7.77 (1H, m, CH), 7.54 - 7.52 
(2H, m, Ar), 4.81 (2H, d, 3JHH = 1.9, CH2), 4.30 – 4.27 (2H, m, CH2), 4.20 (5H, s, Cp), 4.05 
(2H, d, 3JHH = 1.9, Cp), 1.42 - 1.38 (6H, m, 3CH2), 0.94 - 0.90 (3H, m, CH3). 
13C (CDCl3) 
126 MHz.  = 176.6, 163.1, 147.4, 139.0, 132.9, 128.0, 127.5, 125.2, 115.9, 111.9, 94.4, 
69.2, 64.6, 62.0, 54.4, 28.7, 28.8, 22.2, 13.8. HRMS-ESI (m/z) found 443.1412, calc. for 
[C25H26FeN2O2 + H]
+  443.1416. Elemental Analysis: calcd (%) C, 67.88; H, 5.92; N, 6.33 
for C25H26FeN2O2: Fnd (%) C, 67.87; H, 6.05; N, 6.45. 
N-Ferrocenyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (11c). 
1-(2-Morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (30.2 mg, 0.1 mmol) 
was reacted with HOBt (6.8 mg, 0.05 mmol) , HBTU (57 mg, 0.15 mmol) and DIPEA (0.035 
mL) in CHCl3 solution (2 mL). The reaction mixture was stirred at RT for 45 min. and then 
aminoferrocene (24.1 mg, 0.12 mmol) was added and the mixture was stirred for 24 h. Work-
up was as above. The orange band was eluted with a hexane: ethyl acetate (3:7) mixture, and 
was collected and evaporated to dryness. The yield was 23 mg, 47% (yellow solid). 
Crystallization by diffusion between acetone and hexane provided orange crystals. 1H NMR 
(CDCl3) 500 MHz.  = 11.46 (1H, s, NH), 8.84 (1H, s, CH), 8.60 (1H, dd, 3JHH = 8.1, 4JHH = 
1.5, CH), 7.79 – 7.76 (1H, m, CH), 7.58 - 7.54 (2H, m, Ar), 4.82- 4.79 (1H, m, CH), 4.39 
(2H, d, 3JHH = 1.9, CH2), 4.20 (5H, s), 4.13 – 4.11 (1H, m, CH), 4.08 – 4.05 (1H, m, CH), 
3.70 – 3.68 (2H, m, CH2), 2.85 – 2.83 (1H, m, CH), 2.53 (2H, m, CH2), 2.05 (1H, s, CH), 
1.29 -1.26 (3H, m).  13C (CDCl3) 126 MHz.  = 176.6, 162.9, 148.2, 139.0, 133.0, 128.0, 
127.6, 125.2, 115.6, 111.8, 94.3, 69.2, 66.8, 64.6, 62.0, 56.5, 53.8, 51.4. HRMS-ESI (m/z) 
found 486.1471, calcd. for [C26H27FeN3O3 + H]
+ 486.1475. Elemental Analysis. Calcd (%) C, 
64.34; H, 5.61; N, 8.66 for C26H27FeN3O3: Fnd (%) C, 64.27; H, 5.54; N, 8.63. 
N-Ferrocenyl-6-methyl-4-oxo-1-pentyl-1,4-dihydropyridine-3-carboxamide (12a). 6-
Methyl-4-oxo-1-pentyl-1,4-dihydropyridine-3-carboxylic acid (22.3 mg, 0.1 mmol) was 
combined with HOBt (6.8 mg, 0.05 mmol) , HBTU (57 mg, 0.15 mmol) and DIPEA (0.035 
mL) in CHCl3 (2 mL). The reaction mixture was stirred at RT for 45 min and then 
aminoferrocene (24.1 mg, 0.12 mmol) was added. Work-up was as above. The orange band 
was eluted with a hexane: ethyl acetate (2:3) mixture, and was collected and evaporated to 
dryness. The yield was 21 mg, 52% (orange oil). 1H NMR (CDCl3) 500MHz.  = 11.72 (1H, 
s, NH), 8.45 (1H, s, CH), 6.46 (1H, s, CH), 4.88- 4.84 (2H, m, CH2), 4.24 (5H, s, Cp), 4.15 – 
4.12 (2H, m, CH2), 3.91 (2H, d, 
3JHH = 1.9, Cp), 2.39 (3H, s, CH3), 1.80- 1.76 (2H, m, CH2), 
1.38 – 1.32 (4H, m, 2CH2), 0.94 – 0.90 (3H, m, CH3). 13C (CDCl3) 126 MHz.  = 177.4, 
162.4, 147.8, 144.9, 121.4, 118.9, 69.6, 65.0, 62.0, 53.9, 30.6, 29.7, 28.5, 22.2, 19.0, 13.8. 
HRMS-ESI(m/z)  found  407.1414 , calc. for [C22H26FeN2O2 + H]
+  407.1416. LCMS purity 
(UV) = 100%, Ret. Time 19.13 min. LCMS purity (Positive ion, TIC) = 93.5%,  Ret. Time 
19.20 min. 
6-tert-Butyl-N-ferrocenyl-4-oxo-1-pentyl-1,4-dihydropyridine-3-carboxamide (12b). 6-
(tert-Butyl)-4-oxo-1-pentyl-1,4-dihydropyridine-3-carboxylic acid (26.5 mg, 0.1 mmol) was 
combined with HOBt (6.8 mg, 0.05 mmol) , HBTU (57 mg, 0.15 mmol) and DIPEA (0.035 
mL) in CHCl3 (2 mL). The reaction mixture was stirred at RT for 45 min. and then 
aminoferrocene (24.1 mg, 0.12 mmol) was added and the mixture was stirred for 24 h. Work-
up was as above.  The orange band was eluted with a hexane: ethyl acetate (1:1) mixture, 
which was collected and evaporated to dryness. The yield was 22 mg, 49% (orange oil). 1H 
NMR (CDCl3) 500 MHz.  = 11.70 (1H, s, NH), 8.48 (1H, s, CH), 6.66 (1H, s, CH), 4.78 – 
4.76 (2H, m, CH2), 4.16 (5H, s, Cp), 4.13 – 4.10 (2H, m, CH2) 4.04 - 4.02 (2H, m, CH2), 2.19 
– 2.15 (2H, m, CH2), 1.46 (9H, s, t-Bu), 1.42 – 1.38 (4H, m, 2CH2), 0.98 - 0.92 (3H, m, CH3). 
13C (CDCl3)  126 MHz. 177.7, 162.4, 158.5, 147.0, 119.0, 118.2, 110.0, 94.0, 69.2, 64.6, 
62.1, 59.5, 54.9, 35.8, 32.0, 30.4, 28.7, 22.2, 13.9. HRMS-ESI(m/z)  found  449.1886, calc. 
for [C25H32FeN2O2 + H]
+  449.1886. LCMS purity (UV) = 100%, Ret. Time 23.68 min. 
LCMS purity (Positive ion, TIC) = 96.8%, Ret. Time 23.76 min. 
N-Ferrocenyl-4-oxo-1-pentyl-6-phenyl-1,4-dihydropyridine-3-carboxamide (12c). 4-
Oxo-1-pentyl-6-phenyl-1,4-dihydropyridine-3-carboxylic acid (28.5 mg, 0.1 mmol) was 
reacted with HOBt (6.8 mg, 0.05 mmol) , HBTU (57 mg, 0.15 mmol) and DIPEA (0.035 mL) 
in CHCl3 (2 mL). The reaction mixture was stirred at RT for 45 min. and then 
aminoferrocene (24.1 mg, 0.12 mmol) was added and the mixture stirred for 24 h. Work-up 
was as above. The orange band was eluted with a hexane: ethyl acetate (1:1) mixture, which 
was collected and evaporated to dryness. The yield was 29 mg, 62% (orange solid). 1H NMR 
(CDCl3) 500 MHz.  = 11.80 (1H, s, NH), 8.61 (1H, s, CH), 7.56- 7.52 (3H, m, Ar), 7.39 – 
7.35 (2H, m, Ar), 6.54 (1H, s, CH), 4.80 (2H, d, 3JHH =  1.9, CH2), 4.20 (5H, s, Cp), 4.05 (2H, 
d, 3JHH =  1.9, CH2), 3.85 – 3.83 (2H, m, CH2), 1.65 – 1.61 (2H, m, CH2), 1.18 – 1.16 (4H, m, 
2 CH2), 0.81 (3H, t, 
3JHH = 7.1, CH3). 
13C (CDCl3) 126 MHz.  = 177.1, 162.4, 151.8, 144.8, 
133.2, 130.1, 129.0, 128.5, 122.4, 119.4, 93.9, 69.2, 64.7, 62.1, 54.4, 30.6, 28.2, 21.9, 13.7. 
HRMS-ESI(m/z)  found  469.1576 , calc. for [C27H28FeN2O2 + H]
+  469.1573. Elemental 
Analysis: calcd (%) C, 69.24; H, 6.03; N, 5.98 for C27H28FeN2O2: Fnd (%) C, 68.89; H, 6.13; 
N, 5.81. 
1-Cyclohexyl-N-ferrocenyl-N-methyl-4-oxo-1,4-dihydroquinoline-3- carboxamide (13a).               
The title compound was prepared by reacting 11a (110 mg, 0.2 mmol) with NaH (10 mg, 0.4 
mmol) in dry DMF(5 mL). The reaction mixture was stirred at RT for 20 min and then 
iodomethane (45 µL, 0.7 mmol) was added. After stirring at RT overnight the mixture was 
extracted with EtOAc, then washed with brine, H2O dried over MgSO4 and evaporated. A 
yellow band was eluted, using chromatography, with a hexane: ethyl acetate (2:3) mixture, 
collected and evaporated to dryness. The yield was 38 mg, 41% (yellow solid). 
Crystallization by diffusion between CH2Cl2 and hexane provided yellow crystals. HRMS-
ESI(m/z)  found  469.1576 , calcd. for [C27H28FeN2O2 + H]
+  469.1573. Elemental Analysis; 
calcd (%) C, 69.24; H, 6.03; N, 5.98 for C27H28FeN2O2: Fnd (%) C, 69.19; H, 6.10; N, 6.03. 
LCMS purity (UV) = 100%, Ret. Time 18.20 min.  LCMS purity (Positive ion, TIC) = 
91.6%, Ret. Time 18.27 min. 
 
Competition binding assay: Stock solutions of the compounds were prepared in DMSO and 
further diluted with the binding buffer to the desired concentration. Briefly, [3H]-CP-55,940 
(0.5 nM), non selective human CB1 and CB2 cannabinoid receptor was added to 6 μg of 
membranes from CB1- or CB2-overexpressing CHO cells in binding buffer (50 mM Tris-HCl, 
5 mM MgCl2, 2.5 mM EDTA, 0.5mg/mL BSA, pH 7.4 ). After 90 min at 30 °C, the 
incubation was stopped and the solutions were rapidly filtered over UniFilter-96 GF/C glass 
fiber plate, pre-soaked in PEI (0.05%) on a Filtermate UniFilter 96-Harvester (PerkinElmer) 
and washed 10 times with ice-cold 50 mM Tris-HCl pH 7.4. The radioactivity on the filters 
was measured using a TopCount NXT Microplate Scintillation Counter (PerkinElmer) using 
30 μL of MicroScint 40 (PerkinElmer). Assays were performed at least in triplicate in three 
independent experiments. The nonspecific binding was determined in the presence of 5 μM 
(R)-(+)-WIN 55,212-2 (Sigma). 
Cell-based HTRF cAMP assay: Cellular cAMP levels were measured using reagents 
supplied by Cisbio International (HTRF dynamic 2 cAMP kit). Briefly, CHO-CB2 cells were 
harvested and were collected by centrifugation for 5 min at 1200 rpm. The cells were then 
resuspended in an appropriate final volume of culture medium and incubated with the 
phosphodiesterase inhibitor IBMX (0.5 mM). Cells were incubated for 15 min with the 
compounds at room temperature in a 384-well plate (2000 cells per well) before the addition 
of forskolin (3 µM) for 30 min. at room temperature. The dye d2-conjugated cAMP and 
Europium cryptate-conjugated anti-cAMP antibodies were added to the assay plate, 
according to manufacturer’s instructions. After 1 hour incubation at room temperature, the 
plate was read on a Spectramax microplate reader (Molecular Devices) with excitation 
wavelength at 340 nm and emission wavelengths at 665 nm and 620 nm. 
Cell culture and proliferation assay: CHO-WT, CHO-CB2, and HT29 cells were grown 
at 37°C in a humidified atmosphere containing 5 % CO2, in DMEM-GlutaMAX medium 
(Life technologies) supplemented with 10 % fetal bovine serum, penicillin (100 IU/mL), and 
streptomycin (100 µg/mL). In the cell proliferation assay, cells were plated in triplicate on 
96-well plates (3.103 cells per well) and incubated for 24 h. Cells were then incubated in 
culture medium that contained 10 µM tested compounds. After 72 h, cell growth was 
estimated by the colorimetric MTS test. 
X-ray Crystallography. Single-crystal X-ray diffraction analyses were performed using a 
Rigaku FRE+ equipped with either VHF (11a, 11c) or HF Varimax confocal mirrors (11b, 
13a) and an AFC10 goniometer and HG Saturn 724+ detector equipped with an Oxford 
Cryosystems low-temperature apparatus operating at T = 100(2) K.62 CrystalClear-SM Expert 
3.1 b2763 was used to record images, process data and apply empirical absorption corrections 
and unit cell parameters were refined against all data. The structures were solved by charge 
flipping using SUPERFLIP64 and refined on Fo2 by full-matrix least-squares refinements 
using SHELXL-201265 as implemented within OLEX2.66 All non-hydrogen atoms were 
refined with anisotropic displacement parameters and hydrogen atoms were. Hydrogen atoms 
were added at calculated positions except those attached to heteroatoms which were located 
from the difference map and restrained to a reasonable geometry.  All hydrogen atoms were 
refined using a riding model with isotropic displacement parameters based on the equivalent 
isotropic displacement parameter (Ueq) of the parent atom. Figures were produced using 
OLEX2iv. The CIF files for the crystal structures of 11a-c and 13a have been deposited with 
the CCDC and have been given the deposition numbers 1479553-1479556 respectively. 
 
Supporting Information. Contains scanned 1H, 13C NMR spectra for all compounds 
synthesized herein. 
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Abbreviations Used: 
cAMP, cyclic adenosine monophosphate;  
CHO-WT, Chinese hamster ovary cells wild type; 
CHO-CB2, Chinese hamster ovary cells expressing CB2 receptors; 
GPCR, G protein-coupled receptor; 
HBTU, O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
SNL, spinal nerve ligation;  
SI, selectivity index; 
TNBS, 2,4,6-trinitrobenzenesulfonic acid; 
VT, variable temperature. 
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